CL
CHRS icon

Croft-Leominster’s Coherus Oncology CHRS Stock Holding History

Croft-Leominster’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,000
Closed -$287K – 129
2017
Q2 		$287K Hold
20,000
– – 0.07% 106
2017
Q1 		$423K Buy
+20,000
New +$492K 0.1% 91
2016
Q4 		– Sell
-15,000
Closed -$420K – 96
2016
Q3 		$401K Buy
+15,000
New +$409K 0.1% 95

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Croft-Leominster's CHRS Position: Q3 2017 in Review

Croft-Leominster sold out of Coherus Oncology (CHRS) in Q3 2017, closing a stake of 20,000 shares — an estimated $287K sold.

Croft-Leominster first reported a position in CHRS in Q3 2016 and held it in 3 quarters. The position peaked at $423K in Q1 2017. 93 funds tracked by Wall St. Rank hold CHRS as of Q3 2017.

  • Croft-Leominster reported no remaining Coherus Oncology position as of Q3 2017 after selling out during the quarter.
  • Croft-Leominster sold 20,000 Coherus Oncology shares in Q3 2017, an estimated $287K.
  • Croft-Leominster first reported a position in Coherus Oncology in Q3 2016 and held it in 3 quarters.
  • Croft-Leominster's Coherus Oncology position peaked at $423K in Q1 2017.
  • 93 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2017.

Based on Croft-Leominster's 13F filing for Q3 2017, filed 14 Nov 2017.